Zoetis Inc. is rated a hold because its shares currently trade near their intrinsic value, offering limited upside potential despite the company's leadership in the veterinary sector and steady growth prospects. The company expects 3-5% organic operational growth by 2026 and maintains shareholder-friendly policies, including a 20% dividend growth over five years and a 6.6% buyback yield. However, risks such as pipeline concentration, increasing competition, and setbacks like a 32% sales decline in Librela due to safety concerns temper the outlook. The stock's fair value is estimated at around $118.39, close to its current price of $118.18, suggesting limited room for price appreciation.
Pomerantz LLP has filed a class action lawsuit against Zoetis Inc., alleging securities fraud and other unlawful practices following the company's announcement of a profit guidance cut for 2026. Zoetis reported flat net income of $601 million for Q1 ...
Pomerantz LLP has filed a class action lawsuit against Zoetis Inc., alleging securities fraud linked to the company's lowered 2026 profit guidance and a significant stock price drop. Zoetis reported flat net income for Q1 2026 and reduced its full-ye...
Zoetis, once a high-performing stock, has fallen about 70% from its peak in December 2021, mainly because its U.S. companion animal business saw an 11% organic decline in Q1 2026 after strong growth in 2021. The decline is linked to weaker U.S. consu...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by rising demand for rapid diagnostics, AI integration, and precision veterinary medicine, alongside i...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by increasing demand for rapid diagnostics, AI integration, robotic workflows, and a focus on companio...
